Biological
Heptavalent Pneumococcal Conjugate Vaccine clinical trials
- studies test it
- 41
- open now
- 0
- in phase 3
- 15
- first study started
- 2002
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
41 studies that test it; most in 2006 (9)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 9 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 10
- Phase 3
- 15
- Phase 4
- 11
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 24
GlaxoSmithKline (6) · Wyeth is now a wholly owned subsidiary of Pfizer (4) · Sanofi Pasteur, a Sanofi Company (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · The Hospital for Sick Children (2) · Pfizer (2) · Assistance Publique - Hôpitaux de Paris (1) · Emory University (1)
Often tested with
Tested in the same studies.
Pneumococcal Vaccines (6) · 23-valent pneumococcal capsular polysaccharide vaccine (2) · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (2) · Hepatitis A Vaccines (2) · Chickenpox Vaccine (2) · Pediarix (2) · PHiD-CV vaccine (1) · Poliovirus Vaccine, Oral (1)
Studies
Open first, then newest update. How each study uses Heptavalent Pneumococcal Conjugate Vaccine is read from its arms, and is right about nine times in ten.
Testing it · 41
- Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus ErythematosusCompletedPhase 2/3Assistance Publique - Hôpitaux de ParisNCT00611663Written as Prevenar® and Pneumo23®
- Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV DrugsCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00257127Written as Pneumococcal 7-valent conjugate vaccine
- Antibody Production in Immune DisordersTerminatedPhase 4National Institute of Allergy and Infectious Diseases (NIAID)NCT00023504Written as Prevnar
- Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ TransplantsCompletedPhase 3The Hospital for Sick ChildrenNCT00213265Written as 7-valent pneumococcal conjugate vaccine
- Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00624819Written as Prevenar
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT01098474Written as Prevnar™
- Systems Biology of PNEUMOVAX®23 and PREVNAR 13®CompletedNot applicableEmory UniversityNCT01307449Written as Prevnar
- Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm InfantsCompletedPhase 3GlaxoSmithKlineNCT00586612Written as Prevenar™
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) VaccineCompletedPhase 2GlaxoSmithKlineNCT00127855Written as Prevenar®
- Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00289783Written as Prevnar
- Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of AgeCompletedPhase 3GlaxoSmithKlineNCT00197002Written as Prevnar™
- Pneumococcal Adult-dose Ranging Immunization StudyCompletedPhase 1/2Kaiser PermanenteNCT00169234Written as PCV7, Prevnar®
- Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)CompletedPhase 4Merck Sharp & Dohme LLCNCT00312858Written as Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00343421Written as PEDIACEL® and Prevenar®
- PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus PneumoniaeCompletedNot applicableCenters for Disease Control and Prevention, ChinaNCT02133469Written as PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)
- Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)CompletedPhase 3PfizerNCT00617760Written as Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)
- Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary DiseaseCompletedPhase 3University of MinnesotaNCT00457977Written as Prevnar (PCV7)
- Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy InfantsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01444781Written as DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide
- Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy InfantsCompletedPhase 2Novartis VaccinesNCT00262002Written as Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)
- Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai InfantsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00401531Written as DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines
See all 41 studies that test Heptavalent Pneumococcal Conjugate Vaccine →
Given in every arm · 14 — Heptavalent Pneumococcal Conjugate Vaccine is usual care beside what is tested
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT01049035Written as Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
- A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedPhase 1/2Abramson Cancer Center at Penn MedicineNCT01312389Written as Prevnar
- Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT00861744Written as Prevnar®
- Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in ChildrenTerminatedPhase 2GlaxoSmithKlineNCT01003418Written as Prevenar
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of AgeCompletedPhase 2GlaxoSmithKlineNCT00578175Written as Prevnar®
- Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal VaccineCompletedPhase 2GlaxoSmithKlineNCT00129129Written as Prevnar
- Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate VaccinesCompletedPhase 2GlaxoSmithKlineNCT00134719Written as Prevenar®
- Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in InfantsCompletedPhase 2GlaxoSmithKlineNCT00871338Written as Prevenar™
- Humoral Determinants of Immunity to Pneumococcal InfectionCompletedPhase 4VA Office of Research and DevelopmentNCT00304382Written as Prevnar
- V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)CompletedPhase 3Merck Sharp & Dohme LLCNCT00109343Written as Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)
- Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.CompletedPhase 3GlaxoSmithKlineNCT00345683Written as Prevnar
- Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.CompletedPhase 2GlaxoSmithKlineNCT00729001Written as Prevnar
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsCompletedPhase 3Novartis VaccinesNCT00474526Written as Pneumococcal 7-valent Conjugate Vaccine
- Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and ToddlersCompletedPhase 3Novartis VaccinesNCT00667602Written as PCV7
As the comparator · 23 — what is tested is compared with Heptavalent Pneumococcal Conjugate Vaccine
- Clinical Trial of PCV24 in Infants Aged 2-23 MonthsRecruitingPhase 1Sinovac Life Sciences Co., Ltd.NCT06800261Written as Prevnar®
- Clinical Trial of 13-Valent Pneumococcal Conjugate VaccineRecruitingPhase 3Sinovac Life Sciences Co., Ltd.NCT06617715Written as Prevnar®
- Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsRecruitingPhase 2Sinovac Life Sciences Co., Ltd.NCT07300644Written as Prevnar®
- A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In ChinaCompletedPhase 3PfizerNCT01692886Written as 7-valent Pneumococcal Conjugate Vaccine
- Study of Gamma PN3 in the ElderlyCompletedPhase 1GPN VaccinesNCT06562790Written as Prevnar
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric PopulationCompletedPhase 3Valneva Austria GmbHNCT01041573Written as Prevnar
- Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)CompletedPhase 3Walvax Biotechnology Co., Ltd.NCT02736240Written as 7-valent pneumococcal conjugate vaccine
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedPhase 3GlaxoSmithKlineNCT00463437Written as Prevenar
- Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/HibCompletedPhase 3GlaxoSmithKlineNCT00652951Written as Prevenar™
- Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.CompletedPhase 3GlaxoSmithKlineNCT00370396Written as Prevenar
- Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)CompletedPhase 1Merck Sharp & Dohme LLCNCT01215175Written as Prevnar™
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same VaccinesCompletedPhase 3GlaxoSmithKlineNCT00547248Written as Prevenar (Wyeth)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00344318Written as Prevenar
- Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™CompletedPhase 3GlaxoSmithKlineNCT00680914Written as Prevenar
- Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedPhase 3Novartis VaccinesNCT00657709Written as Prevenar
- Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 VaccineCompletedPhase 2GlaxoSmithKlineNCT00323622Written as Prevnar™
- Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With PrevnarCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00594347Written as Prevnar
- Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy InfantsCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00474539Written as 7-valent pneumococcal conjugate vaccine
- Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.CompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00368966Written as 7-valent Pneumococcal Conjugate Vaccine
- Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00366678Written as 7-valent pneumococcal conjugate vaccine
Showing 20 of 23.
Codes
What other systems call Heptavalent Pneumococcal Conjugate Vaccine · ClinicalTrials.gg INT006577
- MeSH (NLM) D000069443Heptavalent Pneumococcal Conjugate VaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069443 | Heptavalent Pneumococcal Conjugate Vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.